C the Signs has been selected as part of the inaugural White House CancerX Accelerator, a major U.S. initiative uniting global leaders in oncology, technology, and innovation to deliver on President Biden’s Cancer Moonshot vision - to reduce cancer mortality by 50% over the next 25 years.
This marks an extraordinary moment for C the Signs - and for the UK’s role in global healthcare innovation - as the only British company chosen among the 16 organisations forming the first CancerX Accelerator cohort.
Transforming Early Diagnosis on a Global Stage
Built within the NHS and founded by UK doctors, C the Signs is redefining how cancer is detected.
The platform uses artificial intelligence to help clinicians identify patients at risk of cancer at the earliest and most treatable stage.
So far, the system has:
- Identified over 25,000 patients with cancer,
- Achieved 98% accuracy in identifying risk, and
- Supported clinicians across 1,500+ GP practices in finding cancer faster and earlier.
Through the CancerX Accelerator, C the Signs joins forces with leading organisations including AstraZeneca, Intel, Dell Technologies, AWS, and UC Davis Health - forming part of a global collaboration dedicated to transforming the future of cancer care.
“A Pivotal Moment to Lead with Heart”
“As a doctor, I am deeply moved and profoundly grateful for our selection to participate in the inaugural CancerX Accelerator,” said Dr Bea Bakshi, CEO and Co-Founder of C the Signs.
“At C the Signs, our mission is rooted in the belief that early detection can change the course of this disease - aiming for a future where surviving cancer is the norm, not the exception. This is more than an opportunity; it’s a pivotal moment to lead with heart and create meaningful change.”
Recognising UK Leadership in Health Innovation
“This recognition is a testament to the UK’s leadership in healthcare innovation and our capacity to create technology solutions with a global impact,” said Aphrodite Spanou, Director of Healthcare UK at the Department of Health and Social Care, NHS England, and the Department for Business and Trade.
“C the Signs’ work in early cancer detection not only exemplifies British ingenuity but also demonstrates how local innovation can achieve international significance.”
Bringing Together AI and Oncology to Rewrite the Possible
The CancerX Accelerator provides a unique opportunity for cross-sector collaboration - connecting C the Signs with cancer experts, research networks, and innovation partners across the United States.
This partnership represents more than recognition; it’s the next step in scaling early cancer detection globally, combining UK clinical excellence with international innovation to help save lives worldwide.
About C the Signs
Founded by NHS doctors Dr Bea Bakshi and Dr Miles Payling, C the Signs is an AI-powered clinical platform that enables healthcare professionals to identify patients at risk of cancer earlier, faster, and more accurately.
Validated through peer-reviewed research and partnerships with NHS England, Health Innovation Networks, and now the White House CancerX Accelerator, C the Signs continues to redefine what’s possible in early cancer detection - giving people back time, choice, and life.
📢 Read more about the White House CancerX Accelerator: https://cancerx.health/accelerator
🌐 Learn more about C the Signs: www.cthesigns.com